Puru Nanjappa
About Puru Nanjappa
Puru Nanjappa is a Research Scientist in Discovery Pharmacology at Bristol Myers Squibb, with extensive experience in cancer therapeutics and a strong background in cellular and molecular medicine.
Current Position at Bristol Myers Squibb
Puru Nanjappa is currently employed as a Research Scientist specializing in Discovery Pharmacology at Bristol Myers Squibb, located in Cambridge, Massachusetts. His role involves contributing to IND-enabling studies and developing high-throughput screening assays for genomic instability markers. His work at Bristol Myers Squibb capitalizes on his extensive experience in multi-color Flow cytometry, qRT-PCRs, SDS-PAGE, ELISA, and enzyme assays.
Previous Roles in the Biotechnology Sector
Puru Nanjappa has accumulated significant experience in the biotechnology sector. He worked at Compass Therapeutics LLC as Scientist I from 2017 to 2021 in Boston, Massachusetts. Before that, he spent a decade at Dana-Farber Cancer Institute as Lead Research Associate from 2007 to 2017. He also worked at Schepens Eye Research Institute, affiliated with Harvard Medical School, as a Research Technician from 2006 to 2007. Earlier in his career, he served as a Research Assistant at Ottawa Health Research Institute and CAREG, in Ottawa, Canada, from 2003 to 2006.
Academic Background and Research Expertise
Puru Nanjappa holds an M.Sc. in Cellular and Molecular Medicine from the University of Ottawa, which he obtained from 2003 to 2006. He also earned an M.Sc. in Aquaculture from the Central Institute of Fisheries Education and a B.F.Sc. in Fisheries Science from Karnataka Veterinary, Animal, and Fisheries Sciences University. His academic training laid the groundwork for his expertise in cancer therapeutics, including xenograft and syngeneic model generation, and the pre-clinical assessment of novel inhibitors and antibodies.
Research Contributions and Publications
Puru Nanjappa has made significant contributions to the scientific community, co-authoring 12 publications that have garnered over 850 citations. His research includes the evaluation of chemical and antibody inhibitor targets, with his work notably contributing to the FDA approval of Panobinostat and Secukinumab (Cosentyx), as well as progressing Anti-DKK1 antibody through phase 2 clinical trials. He presented an influential poster at the Society for Immunotherapy of Cancer (SITC) 2018 conference.